Should I buy ITV stock today?

The ITV stock price is on an upward trend in the past few months. Royston Roche analyses the stock to see if it’s a buying opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The ITV (LSE: ITV) share price rose 40% in the past three months. I believe that the positive trading update in November and the start of vaccinations for Covid-19 drove these stellar returns. 

ITV stock fundamentals

ITV’s revenue grew at a compounded annual growth rate of 2.8% from 2017 to 2019. 2019 revenue was £3.3bn. Revenue for the nine months ended 30 September 2020 fell 16% year-on-year to £1.86bn. The drop in revenue was primarily due to the negative impact from the Covid-19. There is some positive news as the management mentioned that advertising trends are improving with Q4 forecast to be slightly up year-on-year. Also, 85% of the company’s productions in the UK and internationally that was paused due to Covid-19 were back in production or have been delivered.

It has two revenue segments: ITV Studios creates and produces content in the UK and internationally across 13 countries. Year-to-date nine months revenue fell by 19% year-on-year to £902m. The second segment, Broadcast, operates free-to-air commercial channels in the UK and delivers the content through linear television broadcasting and on-demand via the ITV Hub. Year-to-date nine months revenue fell by 13% year-on-year to £1.3bn. 

I looked into a couple of key performance indicators and think they are satisfactory. ITV total viewing hours increased by 2% year-on-year to 12.2bn and ITV Hub registered user accounts increased by 7% year-on-year to 32.1m. The company has a stable balance sheet. It had a net debt of £775m, as of 30 September 2020.

ITV content update

The ITV Hub achieved strong performance in the festive period between 21 December and 3 January, which grew 11% year-on-year. For the entire month of December, it had 81m programme streams, an increase of 5% year-on-year. With a total of 6.9m streams, Coronation Street was the most popular programme on the ITV Hub over Christmas. The return of The Masked Singer was also positive as it hit 0.5m streams on the ITV Hub. The company has secured a deal to bring The Masked Dancer to the UK, which was originated and successful in America. Good Morning Britain also got a very good viewership in December.

The trend continued in the month of January as the ITV Hub exceeded the targets for January 2021 for both consumption hours and monthly active users. The Bay is currently the ITV Hub’s most popular show across the month with 7m streams.

I am a bit worried that the company might lose some advertising revenues due to the negative impact from Covid-19. The recent national lockdown might also have impacted the company’s production in the fourth quarter.  The company is a new player in streaming services and has to face competition from Amazon, Disney, and Netflix.

ITV stock is currently trading at a price-to-earnings ratio of 14.59. The company is innovative and has been able to attract the younger generation’s viewership. I’ll keep ITV stock on my watchlist as I would like to wait for more details on the impact of Covid-19 on the company’s operations. 

Royston Roche has no position in any of the shares mentioned. The Motley Fool UK has recommended ITV. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »